Infantile Encephaloneuromyopathy and Defective Mitochondrial Translation Are Due to a Homozygous RMND1 Mutation  by Garcia-Diaz, Beatriz et al.
REPORT
Infantile Encephaloneuromyopathy
and Defective Mitochondrial Translation
Are Due to a Homozygous RMND1 Mutation
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Defects of mitochondrial protein synthesis are clinically and genetically heterogeneous. We previously described a male infant who was
born to consanguineous parents and who presented with severe congenital encephalopathy, peripheral neuropathy, myopathy, and
lactic acidosis associated with deficiencies of multiple mitochondrial respiratory-chain enzymes and defective mitochondrial transla-
tion. In this work, we have characterized four additional affected family members, performed homozygosity mapping, and
identified a homozygous splicing mutation in the splice donor site of exon 2 (c.504þ1G>A) of RMND1 (required for meiotic nuclear
division-1) in the affected individuals. Fibroblasts from affected individuals expressed two aberrant transcripts and had decreased
wild-type mRNA and deficiencies of mitochondrial respiratory-chain enzymes. The RMND1 mutation caused haploinsufficiency that
was rescued by overexpression of the wild-type transcript in mutant fibroblasts; this overexpression increased the levels and activities
of mitochondrial respiratory-chain proteins. Knockdown of RMND1 via shRNA recapitulated the biochemical defect of themutant fibro-
blasts, further supporting a loss-of-function pathomechanism in this disease. RMND1 belongs to the sif2 family, an evolutionary
conserved group of proteins that share the DUF155 domain, have unknown function, and have never been associated with human
disease. We documented that the protein localizes to mitochondria in mammalian and yeast cells. Further studies are necessary for
understanding the function of this protein in mitochondrial protein translation.Resulting from mitochondrial or nuclear DNA defects,
disorders of mitochondrial protein synthesis have
been reported in a heterogeneous group of individuals
presenting predominantly with prenatal- or congenital-
onset lethal encephalopathies associated with combined
deficiencies of respiratory-chain and oxidative-phos-
phorylation (OXPHOS) enzymes.1–3 Mutations in nuclear
genes have been described in eight mitochondrial trans-
fer-RNA-modifying factors,4–13 three mitochondrial ribo-
somal proteins,14–16 and three mitochondrial elongation
factors.17–22 Additional mutations have been documented
in the gene encoding the translational activator of cyto-
chrome c oxidase (COX) I (TACO1) (MIM 612958)23 and
in C12orf65 (encoded by C12orf65 [MIM 613541]), a
protein belonging to the family of mitochondrial class I
peptide release factors.24
In 2008, we described an 18-day-old male infant (indi-
vidual VI-1 in Figure 1) who was born to consanguineous
parents from Saudi Arabia and who presented with severe
neonatal encephaloneuromyopathy and lactic acidosis.1
At birth, the infant was unresponsive but was successfully
resuscitated and intubated. He had few spontaneous limb
movements and required mechanical ventilation. Exami-
nation revealed prominent tongue fasciculations, bilateral
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The Americarms and legs. Tendon reflexes were absent. He developed
myoclonic jerks and died at the age of 18 months. A
muscle biopsy when he was 24 days old showed severe
COX (complex IV) deficiency. Fibroblasts showed a gener-
alized and severe defect of mitochondrial protein syn-
thesis, reductions of all mitochondrial-translated products,
normal mitochondrial transcript levels, reduction in the
steady-state levels of complexes I, IV, and V, and a normal
complex II (encoded entirely by nuclear genes).1 We have
now characterized four additional affected familymembers
and have performed homozygosity mapping in the family
(Figure 1). Three affected infants (VI-3, VI-7, and VI-8)
similarly presented with severe neonatal encephaloneur-
omyopathy at birth and showed lethargy, respiratory
failure, profound floppiness, hyporeflexia or areflexia,
equinus deformities, lactic acidosis, and death in the
first year of life, whereas the fifth affected individual
(VI-9) was stillborn and did not have skeletal deformities
(Table S1, available online). Deficiencies in the activity of
multiple mitochondrial respiratory-chain enzymes were
confirmed in individual VI-3 fibroblasts (Table 1).
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Figure 1. Pedigree of the family
The following symbols are used: black
symbols, affected individuals; open sym-
bols, unaffected relatives; small black sym-
bols, stillborns; diagonal lines, deceased
persons; and asterisks, DNA available.to standard procedures. To identify areas of shared homo-
zygosity among affected individuals, we performed a high-
density genome-wide genotyping of four affected and
eight unaffected relatives by using the Illumina 660W-
Quad gene chip array (Illumina, San Diego, CA), which
features over 650,000 markers across the genome. Clus-
tering, normalization, and genotype calls were performed
with the dedicated GenomeStudio 2010.3 Genotyping
Module (Illumina). SNP genotypes were analyzed in
PLINK software for standard quality controls.25 Genome-
wide homozygosity mapping, which we conducted with
the Homozygosity Mapper program by using default
parameters and restricting the analysis to areas of homo-
zygosity shared between all affected individuals, identified
a single region of homozygosity shared identically by
descent in all affected individuals (Figure S1A). This region
spanned <1Mb between markers rs519861 and rs926777
in 6q25 and included only seven coding genes (Fig-
ure S1B). We sequenced all exons of the seven genes
included in the candidate locus by dideoxy DNA sequenc-
ing. All affected individuals were homozygous for a G-to-A
transition (c.504þ1G>A) in the canonical splice donor
site of exon 2 of the long isoform of RMND1 (RefSeq
accession number NM_017909.2) (Figure 2). Parents
were carriers, four unaffected siblings were found to be
heterozygous, and two were homozygous for the wild-
type allele. This variant was absent in 210 control alleles,
as well as in dbSNP 135 and the 1000 GenomesTable 1. Activity of Mitochondrial Respiratory-Chain Enzymes in VI-3 and Control Fibroblasts
Vector or with a Construct Encoding RMND1 Isoform 1
Complex VI-3 Fibroblasts Control Fibroblasts
VI-3 with Empty
Vector
Control with Empty
Vector
IV/CS 0.06 5 0.002 0.69 5 0.02 0.11 5 0.07 0.59 5 0.44
IIþIII/CS 0.05 5 0.001 0.11 5 0.03 0.02 5 0.01 0.05 5 0.02
IþIII/CS 1.1 5 0.88 2.59 5 0.07 0.98 5 0.79 1.75 5 0.77
Activity is expressed in mmol/min/mg protein and is normalized to citrate synthase. Values represent the me
experiments and three different transfections. The following abbreviations are used: complex IV, cytochrome
chrome c reductase; complexes IþIII, nicotinamide dehydrogenase (NADH) cytochrome c reductase; and CS
730 The American Journal of Human Genetics 91, 729–736, October 5, 2012Project. Primers used for sequencing
RMND1 are listed in Table S2.
To evaluate RMND1 mRNA and
protein in fibroblasts from individual
VI-3 and controls, we performed real-
time PCR (RT-PCR) and immunoblot
analyses. RT-PCR analysis of RMND1
showed three transcripts expressed
from the mutant allele: (1) the wild-type (31% 5 1.5), encoding a 449 amino acid protein;
(2) a longer transcript (40% 5 3.5) that has 88 additional
nucleotides and that leads to the insertion of a premature
stop codon at codon 171, 54 amino acids upstream of
the start of the only known functional domain of the
protein (amino acids 225–404); and (3) a shorter variant
(32% 5 2.5), in which a cryptic splice site in exon 2 is
activated and produces an in-frame deletion of 75 nucleo-
tides (25 amino acids) (Figure 2). In addition, quantitative
RT-PCR (qRT-PCR) with a probe that detects all three splice
variants showed mildly reduced RMND1 expression rela-
tive to that of the b-actin (ACTB) transcript in individual
VI-3 compared with the control (Figure 3A). In accordance
with the marked reduction of the wild-type transcript,
immunoblots showed decreased levels of the 52 kDa
band corresponding to the expected RMND1 long isoform
and a 28 kDa band in VI-3 fibroblasts compared with
control fibroblasts (Figure 3B–3C).
To confirm the pathogenicity of the mutation, we
overexpressed RMND1 in VI-3 and control fibroblasts.
Efficiency of overexpression was confirmed by qRT-PCR
and immunoblots (Figure S2). Biochemical activities of
mitochondrial respiratory-chain enzymes, as well as COX
and succinate dehydrogenase (SDH) cytochemistry, were
performed as described.26
In mutant fibroblasts, the biochemical activities of mito-
chondrial enzymes were greater after RMND1 cDNA over-
expression than after empty-vector transfection (Table 1).after Transient Transfection with Empty
VI-3 with RMND1 Control with RMND1
0.14 5 0.08 0.5 5 0.41
0.03 5 0.02 0.04 5 0.02
1.46 5 0.59 1.80 5 1.29
an 5 standard deviation of at least three different
c oxidase (COX); complexes IIþIII, succinate cyto-
, citrate synthase.
Figure 2. Schematic Representation of
RMND1 Wild-Type and Aberrant Tran-
scripts
RMND1 has four splicing variants,
of which only three encode proteins:
ENST00000367303 (12 exons, isoform 1
[I1]), ENST00000367303 (11 exons, iso-
form 2 [I2]), and ENST00000444024 (9
exons, isoform 3 [I3]). All three coding
variants contain a DUF155 domain indi-
cated by a purple box. Coding regions are
represented by blue boxes, and noncoding
regions are represented by white boxes. The longest transcript has a predicted N-terminal 33 amino acid mitochondrial targeting
sequence (MTS). On the left is agarose gel showing the PCR product of RMND1 cDNA from control (C) and VI-3 fibroblasts. ‘‘L’’ indicates
the 100 bp DNA ladder. Splice-site mutation c.504þ1G>A (arrow) produces two aberrant transcripts (AT1 and AT2) and reduces the
amount of wild-type transcript (middle band). The longer transcript, AT1, includes the insertion of 88 nucleotides after exon 2 and
generates a premature stop at codon 171. In the shorter variant, AT2, a cryptic splice site in exon 2 is activated and results in an in-frame
deletion of 75 nucleotides and a protein 25 amino acids shorter than the wild-type. RNA was extracted by the PureLink RNA Mini Kit
(Ambion, Austin, TX) and reverse transcribed into cDNAwith the VILO RT-PCR kit (Invitrogen, Grand Island, NY). RT-PCR of exons 2–7
was performed, and the RT-PCR products were electrophoresed in 2% agarose gels.Specifically, we observed enhanced activities of complexes
IþIII (55.7% 5 5.7 after empty-vector transfection and
90.7% 5 5.7 after RMND1 transfection) and IV (16.3% 5
4.7 after empty vector transfection and 23.3% 5 7.1 after
RMND1 transfection) (Figure 4A). Increased COX activity
without change in baseline normal SDH activity was
confirmed by cytochemistry (Figure S3).
Quantitative evaluation of the steady-state level of respi-
ratory-chain enzyme subunits by immunoblot analyses
with the Total OXPHOS Complexes Detection Kit cocktail
of antibodies (MitoSciences, Eugene, OR, USA) revealed
decreased amounts of mitochondrial-encoded OXPHOS
subunits that increased after transfection with wild-type
RMND1 cDNA. Specifically, after RMND1 overexpression,
as well as after normalization to SDH as a marker of mito-
chondrial mass, there were significant increases in levels of
complex I (51.1% 5 8.0 after empty-vector transfection
and 71.5% 5 17 after RMND1 transfection) and com-
plex IV (47% 5 8.0 after empty-vector transfection and
82% 5 16 after RMND1 transfection) in absolute values
(Figures 4B–4C).
To further investigate the function of RMND1, we used
shRNA-mediated knockdown of the protein. The clone
with the lowest levels of RMND1 transcript and protein
(about 60% of wild-type levels) was chosen for measur-
ing respiratory-chain and OXPHOS activities, steady-state
level, and synthesis (Figure 5).
To assessmitochondrial translation, pulse labeling of cell
cultures from shRNA and control clones was performed as
described1 with slight modifications. Consistent with our
observations in mutant fibroblasts, as compared to wild-
type cells, those with 60% depletion of RMND1 showed
decreased activities of complexes IþIII (75%) and IV
(83%), reduced levels of complexes I (59%) and IV (62%),
and diminished mitochondrial proteins synthesis (60%)
(Figures 5A–5C).
To assess the potential role of RMND1 in the assembly of
ribosomal subunits, we measured 12S and 16S rRNA levels
by qRT-PCR. We did not detect any differences in 12S and
16S rRNAs among mutant skin fibroblasts, RMND1-The Americdepleted HeLa cells, or corresponding wild-type cells
(data not shown).
To confirm the localization of RMND1 in the mito-
chondria of mammalian cells, we performed immunohis-
tochemistry and immunoblots. Fluorescence images,
collected and analyzed by a laser-scanning confocal micro-
scope showed that the fusion protein colocalizeswithmito-
chondria (Figure 6A). An immunoblot of isolated cytosolic
fraction, endoplasmic reticulum (ER), crude mitochondria,
pure mitochondria, and ER þ mitochondria from HeLa
cells showed a 52 kDa band in all fractions and a 28 kDa
band in total cell lysate and in all mitochondrial-contain-
ing fractions (Figure 6B). The 28 kDa band was absent in
both the cytosol and ER fractions (Figure 6B). An immuno-
blot with YFP antibody (1:1000, 632380, Clontech) of
whole 239T cell extracts transfected with a construct en-
coding YFP-RMND1 fusion protein confirmed the speci-
ficity of the two bands, corresponding to the expected
long RMND1 isoform (52 kDa) and to the presumably
cleaved mitochondrial protein (28 kDa) (Figure 6C).
We generate a disrupted version of Saccharomyces cerevi-
siae rmnd1 (RMND1 ortholog) to investigate mitochondrial
function.28,29 Mitochondrial fractionation and intramito-
chondrial localization of Ydr282cp with an antibody
against the HA epitope were performed as described.30
An immunoblot with the HA epitope antibody detected
a ~50 kDa protein (Figure S4).
In accordance with data on the ydr282cmutant strain in
the yeast genome collection, yeast containing the ydr282c-
null allele showed a normal phenotype, including normal
growth in respiration-dependent glycerol medium and
mitochondrial protein synthesis (Figure S5).
Mitochondrial protein synthesis is a complex and still
poorly understood process requiring a number of initia-
tion, elongation, and termination factors, all of which
are encoded by nuclear genes together with mtDNA-
encoded ribosomal and transfer RNA.31 Defects in 18 genes
directly or indirectly involved in mitochondrial pro-
tein synthesis have been described.1,4–25 In muscle and
fibroblasts from an individual with consanguineousan Journal of Human Genetics 91, 729–736, October 5, 2012 731
Figure 3. RMND1 Is Partially Reduced in VI-3 Fibroblasts
(A) qRT-PCR was performed for characterizing the expression level
of RMND1 mRNA in VI-3 fibroblasts with the use of TaqMan
Assays for RMND1 and ACTB (b-actin) transcripts (Applied
Biosystems). Values are expressed as percentages of controls.
Data are represented as the mean 5 standard deviation and are
the results of at least three different experiments. The asterisk (*)
indicates a Student’s t test p < 0.05.
(B and C) Immunoblot for measuring the level of RMND1 in VI-3
fibroblasts. Proteins were extracted, and concentrations were
measured with the BCA Protein Assay Kit (Pierce). Five micrograms
of protein was electrophoresed in a SDS-12%-PAGE gel, transferred
to Immun-Blot PVDF membranes (Biorad, Hercules, CA, USA), and
probed with rabbit polyclonal RMND1 antibody (product
#HPA031399, Sigma-Aldrich, St. Louis, MO) at a 1:1,000 dilution. A
mouse monoclonal actin antibody (Sigma-Aldrich) was used at a
1:10,000 dilution. Protein-antibody interaction was detected with
peroxidase-conjugated goat anti-mouse IgG antibody (1:5,000)
(Sigma-Aldrich) with SuperSignal chemiluminiscence detection kit
(Thermo Fisher Scientific,Waltham,MA). Quantitation of the bands
was performed by densitometric analysis with the National Insti-
tutes of Health ImageJ software package (version 1.45). Values are
expressed as percentages of controls. Data are represented as the
Figure 4. Complementation Analysis in VI-3 and Control Fibro-
blasts
After transient transfection with a construct encoding wild-type
RMND1, mutant cells showed increased biochemical activities of
mitochondrial respiratory-chain enzymes normalized to citrate
synthase (CS) (A) and an increase in the steady-state level of mito-
chondrial OXPHOS subunits (B and C). Values are represented as
the mean5 standard deviation, reflect the results of at least three
different transfection experiments, and are expressed as per-
centages of the untransfected control. The asterisks (*) indicate
a Student’s t test p < 0.05.
732 The American Journal of Human Genetics 91, 729–736, Octoberparents and a fatal infantile-onset encephalomyopathy
with lactic acidosis, we previously demonstrated evidence
of a mitochondrial protein synthesis by documentingmean 5 standard deviation and are the results of at least three
different experiments. The asterisks (*) indicate a Student’s t test
p < 0.05. The following abbreviations are used: C1–C4, controls;
and actin, b-actin.
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Figure 5. Effects of RMND1 Knockdown in HeLa Cells
HeLa cells were cultured in DMEMwith 10% fetal bovine serum (FBS) until they were 70%–80% confluent. Transfection with a scramble
shRNA-pLKO plasmid (negative control) and a RMND1-specific TRC shRNA-pLKO plasmid construct (TRCN0000135730, Sigma Aldrich)
was mediated by Lipofectamine 2000 (Invitrogen). Five hours after transfection, cells were selected with Puromycin in DMEM 2% FBS,
and transfected clones were individually expanded in DMEM 10% FBS. RMND1 knockdown was assessed in 30 clones by qRT-PCR and
immunoblot analysis.
(A) Activity of mitochondrial respiratory-chain enzymes.
(B and C) Immunoblot analysis of the steady-state levels of mitochondrial respiratory enzymes (B) and pulse labeling with [35S] methi-
onine of mitochondrial proteins (C). A total of 53 105 cells cultured in 10 cm culture plates were washed inmethionine-free DMEM and
subsequently incubated in the same medium supplemented with 15% dialyzed FBS, 1.2 mM sodium pyruvate, and glucose for 30 min.
Cytosolic protein synthesis was inhibited by the addition of emetine (0.1 mg/ml) for 7 min at 37C. Mitochondrial proteins were labeled
with 50 mCi [35S]-methionine Redivue (Amersham Biosciences, Piscataway, NJ) in methionine-free medium and incubated for 1 hr at
37C. After treatment, cells were incubated for 10 min in DMEM supplemented with 10% FBS and were collected by scraping. Protein
aliquots (15 mg per sample) were electrophoresed in a 4%–12% Bis-Tris polyacrylamide gradient gel for 4 hr at 85V. The gel was dried for
60 min at 80C and analyzed with a phosphorimager. The seven subunits of complex I (ND), three subunits of complex IV (COX), and
two subunits of complex V (ATP) are indicated at the left. Values are expressed as percentages of the control and are represented as the
mean5 standard deviation. One asterisk (*) indicates a Student’s t test p < 0.05; ** indicates a Student’s t test p < 0.01.severe COX deficiency, partially reduced biochemical
activities of complexes I and V, normal SDH activity, and
decreases of all mitochondrial-translation products with
normal levels of mitochondrial transcripts.1The AmericHere, we report four additional affected relatives, homo-
zygosity mapping, and identification of a homozygous
splice-site mutation in the gene encoding RMND1 in
all four affected individuals. We have shown that thean Journal of Human Genetics 91, 729–736, October 5, 2012 733
Figure 6. RMND1 Localization in Mammalian Cells by Immunohistochemistry and Quantitation by Immunoblot Analysis
(A) RMND1 cDNAwas amplified from a commercial vector containing the human full-length cDNAwith the use of a BamHI-recognition-
site-integrated forward primer 50-AGGATCCGCCATGCCAGCCACACTCCTCAGAGCCG-30 and AgeI-recognition-site-integrated reverse
primer 50-CGACCGGTGATTTCATGGTTGGAAGGTGTG-30. PCR product was digested with BamHI and AgeI and cloned into a pEYFP
expression vector in-frame and upstream of the YFP coding sequence. Fidelity of the fusion RMND1-YFP construct in the expression
vector was verified by sequencing, and 2.5 mg was used for transiently transfecting human embryonic kidney (HEK) 293T cells as
described above. Culture media were supplemented with 0.1 mM MitoTracker Red (Invitrogen) for 30 min before the cells were fixed
with 4% formalin PBS for the detection of mitochondria.
(B) Purification ofmitochondria and cellular fractions was performed as previously described,27 and immunoblot analysis was performed
with primary antibodies anti-RMND1 (1:1,000, Sigma), anti-Complex II (1:5,000, MitoScience, Abcam, Cambridge, MA), anti-APH1a
(1:1,000, Abcam), and anti-Vinculin (1:5,000, Sigma-Aldrich, St. Louis, MO) and either peroxidase-conjugated anti-rabbit (1:2,000) or
peroxidase-conjugated anti-mouse IgG (1:5,000) as a secondary antibody (Sigma-Aldrich). Cellular fractions were isolated from HeLa
cells (25 mg of protein from the total lysate [L]), and equal amounts (6 mg) from each fraction (cytoplasmic fraction [CF], endoplasmatic
reticulum [ER], crude mitochondria [CMt], pure mitochondria [PMt], and ER þ mitochondria [ERMt]) were loaded onto the gel. The
known molecular masses (in kDa) of proteins used for confirming cell-fraction enrichment are indicated in the left margin of the gel.
(C) Immunoblot analysis of total HEK 293T cell extracts transfected with YFP-RMND1 fusion protein with the antibody against green
fluorescent protein confirmed the specificity of the two bands detected by the RMND1 antibody.c.504þ1G>A splice donor mutation reduces the wild-type
transcript and produces two aberrant transcripts. One
alters the reading frame of the protein and produces
a prematurely truncated protein with loss of the DUF155
domain. The other is predicted to produce a protein trun-
cated by 25 amino acids. The fact that the truncated
protein was absent in an immunoblot with an antibody
that recognizes the carboxy-terminus of RMND1 suggests
that this aberrant polypeptide is unstable and degraded.
These data, together with the results of the RNA inter-
ference of the wild-type transcript—showing reduced
mitochondrial protein synthesis in partially depleted
cells—indicate that the disease is caused by loss, rather
than toxic gain, of function. We did not find mutations
in RMND1 in ten other individuals with documented
defects of mitochondrial protein synthesis,2 suggesting
that mutations in RMND1 might be rare.
According to Uniprot, RMND1has at least three isoforms
produced by alternative splicing: isoform 1, the longest one
(449 amino acids), is localized tomitochondria;32 isoform2
(lacking amino acids 1–211); and isoform 3 (containing
alternative amino acids 205–208 DAAN>GTSS andmissing
amino acids 209–449). However, in addition to the pre-
dicted 52 kDa full-length RMND1, immunoblot analysis
revealed a shorter protein (28 kDa), which was abundant
in purifiedmitochondrial fractions; therefore, we postulate
that the 28 kDa RMND1 is the cleaved mitochondrial
protein. We sublocalized the yeast ortholog, Ydr282c, to
the inner mitochondrial membrane with the C terminus
facing the intermembrane space.
RMND1 belongs to the sif2 family, an evolutionary
conserved family of proteins that have unknown function
and that share the DUF155 domain. rmnd1 is conserved in734 The American Journal of Human Genetics 91, 729–736, Octoberspecies down to yeast. The S. cerevisiae ortholog, YDR282C,
has no known functions but has been reported to interact
with the functional ortholog of the human Nieman Pick
C1 protein, which is involved in sphingolipid metabo-
lism.33 Although we have shown that the yeast rmnd1 or-
tholog is a mitochondrial protein, the fact that yeast null
for rmnd1 are viable in glycerol medium indicates that
respiration is not severely affected. Therefore, either the
protein is not involved in yeast mitochondrial protein
synthesis or its function overlaps with those of other
proteins in yeast. In fact, divergent functions in yeast
and humans have been observed for other mitochondrial
proteins, including TACO1, which is required for human
COX I mitochondrial-translation activation, whereas the
yeast ortholog does not serve this function.23 Although
COX deficiency is prominent in the affected indi-
vidual’s muscle and fibroblasts, the involvement of other
respiratory-chain enzymes and the generalized mitochon-
drial-translation defect in mutant fibroblasts and in
RMND1 knockdown cells indicate that RMND1 is not a
COX-subunit-specific translational activator.
Intriguingly, several RMND1 orthologs seem to be
involved in cell division,34 and mitochondrial ribosomal
proteins have been shown to be involved in cell-cycle regu-
lation.35 However, against the notion that RMND1 is a
structural ribosomal protein are the normal levels of 12S
and 16S rRNA in mutant fibroblasts and in RMND1-
depleted HeLa cells because mutations in mitochondrial
small-subunit ribosomal proteins have been shown to
decrease 12S rRNA.14,15
In conclusion, we have identified a human mutation
affecting a DUF155 protein in a family with a severe auto-
somal-recessive mitochondrial-translation defect. Further5, 2012
studies are necessary for understanding the function of
RMND1 and elucidating its role in mitochondrial protein
synthesis.Supplemental Data
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